沙利度胺治疗急性白血病患者的效果及其对外周血调节性T细胞的影响

Abstract
Figure/Table
References (15)
Related Citation (12)

Download: PDF (0 KB) HTML (47 KB)
Export: BibTeX | EndNote (RIS)

Abstract To investigate the effect of Thalidomide on peripheral blood regulatory T cells in the treatment of patients with acute leukemia.Methods Sixty patients with acute myeloid leukemia(AML)admitted to our hospital from January 2014 to January 2018 were selected as the subjects,they were randomly divided into routine group (30 cases)and experimental group(30 cases),the routine group was treated with basic chemotherapy,the experimental group was treated with Thalidomide,and 30 healthy people were selected as the healthy group in the same period.The total effective rate of experimental group and routine group of patients were compared,the levels of CD4+CD25+T lymphocyte in three groups were compared at different time points,the levels of CD3+T lymphocyte,CD4+T lymphocyte,CD4+/CD8+ratio and NK cell in peripheral blood of three groups were compared at different time points.Results The total effective rate of the experimental group was higher than that of the routine group,the difference was significant(P＜0.05).The levels of CD4+CD25+T lymphocyte in the experimental group were higher than those in the healthy group at T1and T2time,the difference was statistically significant(P＜0.05).The levels of CD4+CD25+T lymphocyte in the experimental group were lower than those in the routine group at the time of T2and T3,the difference was statistically significant(P＜0.05).The levels of CD3+T lymphocyte,CD4+T lymphocyte,CD8+T lymphocyte,CD4+/CD8+ratio and NK cell in peripheral blood of the experimental group were lower than those of the healthy group at T1time,the difference was statistically significant(P＜0.05).The levels of CD3+T lymphocyte,CD4+T lymphocyte and NK cell in peripheral blood of the experimental group were higher than those of the routine group at T3time,the difference was statistically significant(P＜0.05).Conclusion Thalidomide can improve the cellular immune function of AML patients and improve the therapeutic effect.

Key words： Acute leukemia Thalidomide Peripheral blood regulatory T cells Cellular immune function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Ju-heng
	ZHAO Ying-ling▲

Cite this article:

LI Ju-heng,ZHAO Ying-ling▲. Effect of Thalidomide on peripheral blood regulatory T cells in the treatment of patients with acute leukemia[J]. 中国当代医药, 2019, 26(8): 77-80.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2019/V26/I8/77

[1]	张乃红.沙利度胺联合常规化疗治疗急性白血病的有效性及安全性评析[J].中国处方药，2015，13（12）：50-51.
[2]	杨敬敬，李焱，杨志峰，等.沙利度胺联合化疗治疗急性白血病临床疗效及对血管生成调控因子的影响[J].疑难病杂志，2013，12（8）：639-640.
[3]	杨艳敏，夏恒志，李一丹，等.丙戊酸钠、沙利度胺联合治疗复发难治急性白血病的临床研究[J].河北医药，2017，39（9）：1379-1381.
[4]	黄维，张庆娟.沙利度胺联合常规化疗治疗急性白血病的疗效分析[J].实用临床医药杂志，2013，17（17）：102-104.
[5]	杨红玲，翟欣辉，魏绪仓，等.沙利度胺配合化疗治疗急性白血病前后血浆VEGF，VEGFR和bFGF测定及意义[J].现代检验医学杂志，2013，28（4）：65-67，70.
[6]	凡治国.沙利度胺治疗急性白血病的疗效及对血管调控因子水平的影响[J].北方药学，2017，14（2）：146-147.
[7]	于果.沙利度胺联合常规化疗治疗急性白血病的疗效分析[J].世界临床医学，2016，10（15）：8.
[8]	徐皓，米瑞华，范瑞华，等.沙利度胺联合干扰素对Kasumi-1细胞的增殖抑制作用及其机制研究[J].中华血液学杂志，2015，36（9）：743-747.
[9]	魏旭东，艾昊，米瑞华，等.沙利度胺联合干扰素、白细胞介素-2治疗复发难治性急性髓系白血病[J].中华内科杂志，2016，55（11）：875-877.
[10]	宋丽君，包慎，冶秀鹏，等.原发性浆细胞白血病合并系统性淀粉样变性一例并文献复习[J].白血病·淋巴瘤，2017，26（1）：57-59.
[11]	陈满强，段明豆.沙利度胺联合CAG方案治疗老年急性髓系白血病的效果及安全性[J].临床医学研究与实践，2018，3（18）：33-34，51.
[12]	艾昊，张龚莉，魏旭东，等.沙利度胺联合干扰素、白细胞介素2治疗复发难治急性髓系白血病长期生存二例并文献复习[J].白血病·淋巴瘤，2017，26（7）：426-429.
[13]	胡花丹.沙利度胺与化疗用于白血病治疗中的临床研究[J].影像研究与医学应用，2017，1（16）：188-189.
[14]	Zheng Y，Tan D，Chen Z，et al.A Non-Genetic Approach to Labelling Acute Myeloid Leukemia and Bone Marrow Cells with Quantum Dots[J].J Nanosci Nanotechnol，2014，14（6）：4014-4021.
[15]	Gao Y，Zhang Y，Kamijima M，et al.Quantitative assessments of indoor air pollution and the risk of childhood acute leukemia in Shanghai[J].Environ Pollut，2014，187：81-89.